Paul Choi Analyst PerformanceBiotechnology Analyst at The Goldman Sachs GroupPaul Choi is a stock analyst at The Goldman Sachs Group focused in the medical sector, covering 28 publicly traded companies. Over the past year, Paul Choi has issued 20 stock ratings, including buy, hold, and sell recommendations. While full access to Paul Choi's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Paul Choi's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings48 Last 9 YearsBuy Recommendations47.92% 23 Buy RatingsCompanies Covered28 Unique Companies Ratings Distribution48RatingsDistribution of strong buy, buy, hold, and sell ratings by Paul Choi.RatingPercentageCount Strong Buy0.0%0 ratings Buy47.9%23 ratings Hold33.3%16 ratings Sell18.8%9 ratingsOut of 48 total stock ratings issued by Paul Choi at The Goldman Sachs Group, the majority (47.9%) have been Buy recommendations, followed by 33.3% Hold and 18.8% Sell.Best & Worst CallsBest Call000.0%VIRApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%INCYApr 2017Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ92.9% of companies on NASDAQ26 companiesNYSE7.1% of companies on NYSE2 companiesPaul Choi, an analyst at The Goldman Sachs Group, currently covers 28 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical27 companies96.4%Energy1 company3.6%Paul Choi of The Goldman Sachs Group specializes in stock coverage within the Medical sector, with additional focus on Energy companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE20 companies71.4%MED - DRUGS4 companies14.3%MED - GENERIC DRG1 company3.6%MED PRODUCTS1 company3.6%SOLAR1 company3.6%LARGE CAP PHARMA1 company3.6% Paul Choi's Ratings History at The Goldman Sachs Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCRVSCorvus Pharmaceuticals4/17/2026Initiated Coverage$15.04$40.00Buy$0.0000.00% ROICRVSCorvus Pharmaceuticals4/17/2026Initiated Coverage$16.74$40.00Buy$0.0000.00% ROIASNDAscendis Pharma A/S3/2/2026Reiterated Rating$233.50$255.00Buy$0.0000.00% ROIRGNXREGENXBIO2/10/2026Lower Price Target$10.31$12.00Neutral$0.0000.00% ROIVERAVera Therapeutics12/19/2025Boost Price Target$47.69$95.00Buy$0.0000.00% ROICYTKCytokinetics12/18/2025Upgrade$59.73$95.00Buy$0.0000.00% ROIPTCTPTC Therapeutics11/5/2025Boost Price Target$71.39$50.00Sell$0.0000.00% ROIBBIOBridgeBio Pharma10/30/2025Boost Price Target$66.62$100.00Buy$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International10/29/2025Boost Price Target$37.75$55.00Buy$0.0000.00% ROIARVNArvinas10/15/2025Reiterated Rating$9.41$6.00Sell$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ARVNArvinas10/15/2025Downgrade$9.46$6.00Sell$0.0000.00% ROILNTHLantheus10/8/2025Set Price Target$51.84$77.00Neutral$0.0000.00% ROILNTHLantheus10/8/2025Reiterated Rating$53.55$77.00Neutral$0.0000.00% ROIEWTXEdgewise Therapeutics9/25/2025Initiated Coverage$16.59$20.00Neutral$0.0000.00% ROIEWTXEdgewise Therapeutics9/24/2025Upgrade$14.89Hold$0.0000.00% ROIEXELExelixis9/17/2025Initiated Coverage$39.14$47.00Buy$0.0000.00% ROIAMRNAmarin6/25/2025Boost Price Target$15.81$12.00Sell$0.0000.00% ROIURGNUrogen Pharma6/13/2025Set Price Target$13.49$16.00Neutral$0.0000.00% ROIURGNUrogen Pharma5/22/2025Lower Price Target$3.91$3.00Neutral$0.0000.00% ROIGOSSGossamer Bio5/16/2025Boost Price Target$1.07$8.00Buy$0.0000.00% ROIPHATPhathom Pharmaceuticals5/2/2025Lower Price Target$2.87$5.00Neutral$00.0000.00% ROIAMRNAmarin4/17/2025Lower Price Target$9.08$7.00Sell$00.0000.00% ROIXENEXenon Pharmaceuticals4/17/2025Lower Price Target$35.24$52.00Buy$00.0000.00% ROIVIRVir Biotechnology4/17/2025Lower Price Target$5.48$21.00Buy$00.0000.00% ROIURGNUrogen Pharma4/17/2025Lower Price Target$10.05$16.00Neutral$00.0000.00% ROIPHATPhathom Pharmaceuticals4/17/2025Lower Price Target$4.12$10.00Neutral$00.0000.00% ROIGOSSGossamer Bio4/17/2025Lower Price Target$0.84$7.00Buy$0.0000.00% ROIPHATPhathom Pharmaceuticals3/10/2025Lower Price Target$4.47$12.00Neutral$00.0000.00% ROIASNDAscendis Pharma A/S2/13/2025Boost Price Target$147.14$225.00Buy$000.0000.00% ROIDVAXDynavax Technologies2/11/2025Downgrade$13.20$12.00Sell$00.0000.00% ROIRGNXREGENXBIO2/11/2025Downgrade$7.89$14.00Neutral$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
